UniProt ID | STX17_HUMAN | |
---|---|---|
UniProt AC | P56962 | |
Protein Name | Syntaxin-17 {ECO:0000303|PubMed:21545355} | |
Gene Name | STX17 {ECO:0000312|HGNC:HGNC:11432} | |
Organism | Homo sapiens (Human). | |
Sequence Length | 302 | |
Subcellular Localization |
Endoplasmic reticulum membrane Multi-pass membrane protein . Smooth endoplasmic reticulum membrane Multi-pass membrane protein . Endoplasmic reticulum-Golgi intermediate compartment membrane Multi-pass membrane protein . Cytoplasmic vesicle, autopha |
|
Protein Description | SNAREs, soluble N-ethylmaleimide-sensitive factor-attachment protein receptors, are essential proteins for fusion of cellular membranes. SNAREs localized on opposing membranes assemble to form a trans-SNARE complex, an extended, parallel four alpha-helical bundle that drives membrane fusion. STX17 is a SNARE of the autophagosome involved in autophagy through the direct control of autophagosome membrane fusion with the lysosome membrane. [PubMed: 23217709] | |
Protein Sequence | MSEDEEKVKLRRLEPAIQKFIKIVIPTDLERLRKHQINIEKYQRCRIWDKLHEEHINAGRTVQQLRSNIREIEKLCLKVRKDDLVLLKRMIDPVKEEASAATAEFLQLHLESVEELKKQFNDEETLLQPPLTRSMTVGGAFHTTEAEASSQSLTQIYALPEIPQDQNAAESWETLEADLIELSQLVTDFSLLVNSQQEKIDSIADHVNSAAVNVEEGTKNLGKAAKYKLAALPVAGALIGGMVGGPIGLLAGFKVAGIAAALGGGVLGFTGGKLIQRKKQKMMEKLTSSCPDLPSQTDKKCS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Phosphorylation | ------MSEDEEKVK ------CCHHHHHHH | 54.47 | 24719451 | |
2 | Acetylation | ------MSEDEEKVK ------CCHHHHHHH | 54.47 | 22814378 | |
7 | Ubiquitination | -MSEDEEKVKLRRLE -CCHHHHHHHHHHHH | 42.49 | 24816145 | |
19 | Ubiquitination | RLEPAIQKFIKIVIP HHHHHHHHHHHHHCC | 42.83 | 29967540 | |
22 | Ubiquitination | PAIQKFIKIVIPTDL HHHHHHHHHHCCCCH | 33.77 | - | |
34 | Ubiquitination | TDLERLRKHQINIEK CCHHHHHHCCCCHHH | 44.44 | 29967540 | |
41 | Acetylation | KHQINIEKYQRCRIW HCCCCHHHHHHHCHH | 42.77 | 19608861 | |
41 | Ubiquitination | KHQINIEKYQRCRIW HCCCCHHHHHHHCHH | 42.77 | 19608861 | |
88 | Ubiquitination | KDDLVLLKRMIDPVK HHHHHHHHHHCHHHH | 35.44 | 29967540 | |
99 | Phosphorylation | DPVKEEASAATAEFL HHHHHHHHHHHHHHH | 23.01 | - | |
102 | Phosphorylation | KEEASAATAEFLQLH HHHHHHHHHHHHHHH | 26.83 | - | |
117 | Ubiquitination | LESVEELKKQFNDEE HHHHHHHHHHCCCCC | 48.05 | 29967540 | |
134 | Phosphorylation | LQPPLTRSMTVGGAF CCCCCCCCEEECCCC | 17.36 | 24275569 | |
157 | Phosphorylation | SQSLTQIYALPEIPQ CCCCHHHHCCCCCCC | 7.71 | - | |
184 | Ubiquitination | ADLIELSQLVTDFSL HHHHHHHHHHHHHHH | 53.21 | 21890473 | |
189 | Ubiquitination | LSQLVTDFSLLVNSQ HHHHHHHHHHHHCCC | 3.96 | 22817900 | |
202 | Phosphorylation | SQQEKIDSIADHVNS CCHHHHHHHHHHHHH | 24.13 | 25849741 | |
209 | Phosphorylation | SIADHVNSAAVNVEE HHHHHHHHHCCCHHH | 19.27 | 22199227 | |
219 | Ubiquitination | VNVEEGTKNLGKAAK CCHHHHCCCHHHHHH | 62.12 | 29967540 | |
227 | Phosphorylation | NLGKAAKYKLAALPV CHHHHHHHHHHHHHH | 13.40 | - | |
273 | Ubiquitination | VLGFTGGKLIQRKKQ CHHHCCHHHHHHHHH | 43.70 | 21890473 | |
278 | Ubiquitination | GGKLIQRKKQKMMEK CHHHHHHHHHHHHHH | 43.08 | 22817900 | |
287 | Phosphorylation | QKMMEKLTSSCPDLP HHHHHHHHHCCCCCC | 29.66 | 27794612 | |
288 | Phosphorylation | KMMEKLTSSCPDLPS HHHHHHHHCCCCCCC | 40.14 | 23401153 | |
289 | Phosphorylation | MMEKLTSSCPDLPSQ HHHHHHHCCCCCCCC | 25.16 | 19664994 | |
295 | Phosphorylation | SSCPDLPSQTDKKCS HCCCCCCCCCCCCCC | 53.67 | 23403867 | |
297 | Phosphorylation | CPDLPSQTDKKCS-- CCCCCCCCCCCCC-- | 54.87 | 23403867 | |
299 | Ubiquitination | DLPSQTDKKCS---- CCCCCCCCCCC---- | 60.10 | 33845483 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of STX17_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of STX17_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
SNP29_HUMAN | SNAP29 | physical | 9852078 | |
VP33A_HUMAN | VPS33A | physical | 24554770 | |
VPS16_HUMAN | VPS16 | physical | 24554770 | |
VPS11_HUMAN | VPS11 | physical | 24554770 | |
VPS18_HUMAN | VPS18 | physical | 24554770 | |
VPS39_HUMAN | VPS39 | physical | 24554770 | |
VPS41_HUMAN | VPS41 | physical | 24554770 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-41, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289, AND MASSSPECTROMETRY. |